Novelix Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|
| Revenue | 22.35 | 20.86 | 5.30 |
| Operating Expense | 22.17 | 20.63 | 5.17 |
| Net Profit | 0.11 | 0.18 | 0.15 |
| Net Profit Margin | 0.49 | 0.86 | 2.83 |
| Earning Per Share | 0.09 | 0.18 | 0.15 |
| EBIDTA | 0.16 | 0.23 | 0.15 |
| Effective Tax Rate | 22.22 | 13.04 | TBA |
| Particulars | Jun 2025 |
|---|---|
| Revenue | 22.35 |
| Operating Expense | 22.17 |
| Net Profit | 0.11 |
| Net Profit Margin | 0.49 |
| Earning Per Share | 0.09 |
| EBIDTA | 0.16 |
| Effective Tax Rate | 22.22 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 30.72 | 4.22 | 1.40 |
| Operating Expenses Annual | 30.57 | 4.47 | 1.92 |
| Operating Profit Annual | 0.16 | 0.06 | -0.00 |
| Interest Annual | TBA | TBA | TBA |
| Depreciation | 0.04 | 0.04 | 0.06 |
| Net Profit Annual | 0.08 | 0.01 | -0.06 |
| Tax Annual | 0.04 | 0.01 | 0.00 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 30.72 |
| Operating Expenses Annual | 30.57 |
| Operating Profit Annual | 0.16 |
| Interest Annual | TBA |
| Depreciation | 0.04 |
| Net Profit Annual | 0.08 |
| Tax Annual | 0.04 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 0.12 | 0.27 | 2.60 |
| Cash Flow from Operations | -13.68 | -0.34 | -2.41 |
| Cash Flow from Investing | 2.93 | 0.19 | 0.08 |
| Cash Flow from Financing | 11.32 | TBA | TBA |
| Cash Flow at the End | 0.68 | 0.12 | 0.27 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 0.12 |
| Cash Flow from Operations | -13.68 |
| Cash Flow from Investing | 2.93 |
| Cash Flow from Financing | 11.32 |
| Cash Flow at the End | 0.68 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 0.52 | 1.42 | TBA |
| PBIT Margin (%) | 0.39 | 0.47 | -3.13 |
| PBT Margin (%) | 0.39 | 0.47 | -3.13 |
| Net PROFIT Margin (%) | 0.26 | 0.24 | -3.13 |
| Return On Networth / Equity (%) | 0.56 | 0.12 | TBA |
| Return On Networth /Employed (%) | 0.84 | 0.24 | TBA |
| Return On Assets (%) | 0.64 | 0.14 | -0.84 |
| Total Debt / Equity (X) | TBA | TBA | TBA |
| Asset Turnover Ratio (%) | 2.47 | 0.58 | 0.27 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 0.52 |
| PBIT Margin (%) | 0.39 |
| PBT Margin (%) | 0.39 |
| Net PROFIT Margin (%) | 0.26 |
| Return On Networth / Equity (%) | 0.56 |
| Return On Networth /Employed (%) | 0.84 |
| Return On Assets (%) | 0.64 |
| Total Debt / Equity (X) | TBA |
| Asset Turnover Ratio (%) | 2.47 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 0.19 | 0.12 | 0.17 |
| Total Current Assets Annual | 26.93 | 4.13 | 4.24 |
| Non Current Assets Annual | 0.27 | 3.24 | 3.01 |
| Total Shareholders Funds Annual | 17.54 | 7.35 | 7.20 |
| Total Assets Annual | 27.21 | 7.36 | 7.26 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 0.19 |
| Total Current Assets Annual | 26.93 |
| Non Current Assets Annual | 0.27 |
| Total Shareholders Funds Annual | 17.54 |
| Total Assets Annual | 27.21 |
EPS (INR)
Expected
0.00
Reported
-0.19
Surprise
0.00%
Jun 2022
EPS beaten by 0.00%
Mar 2022
EPS beaten by 0.00%
Dec 2021
EPS beaten by 0.00%
